As doctors, scientists, and investors try to pick apart which powerful cancer immunotherapy is the best bet for patients, there’s an emerging new tool that might clear up the fog around a whole class of medicines — if its predictive promise can be confirmed in large clinical trials.

It’s called tumor mutation burden, or TMB, and it’s essentially a measure of just how unique a patient’s cancer might be. It could also help doctors identify which patients might benefit from immunotherapies called checkpoint inhibitors.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy